FDA warning on Intercept’s Ocaliva after patient deaths
US regulators have issued a safety communication warning of the risk for serious liver injury and death from incorrect dosing of Intercept Pharmaceuticals’ Ocaliva in patients with primary biliary cholangitis.
Read More





